Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23845818 | 1.00 | TP53 (0.35) | TP53TSHR | |
| SCHEMBL13347845 | 0.91 | — | — | |
| SCHEMBL14218181 | 0.82 | ELANE (0.34) | TSHR | |
| SCHEMBL8129730 | 0.79 | SLC7A5 (0.41) | — | |
| SCHEMBL22908218 | 0.76 | — | — | |
| SCHEMBL21792232 | 0.76 | — | — | |
| SCHEMBL23581471 | 0.76 | TSHR (0.35) | TSHR | |
| SCHEMBL13347849 | 0.75 | — | — | |
| SCHEMBL22258097 | 0.75 | TSHR (0.32) | TSHR | |
| SCHEMBL18256727 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292548-A1 | COMPOSITE POWDER CONTAINING CALCIUM CARBONATE AND HAVING MICROSTRUCTURED PARTICLES HAVING INHIBITING CALCIUM CARBONATE | SCHAEFER KALK GMBH & CO. KG (DE) | 2021-09-23 | — | — | US | disclosed |
| US-9737605-B2 | Injectable controlled release composition comprising high viscosity liquid carrier | DURECT CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160303242-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | DURECT CORPORATION (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160296627-A1 | INTRACAMERAL IMPLANT FOR TREATMENT OF AN OCULAR CONDITION | ENVISIA THERAPEUTICS INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160199387-A1 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2016090103-A1 | BIODEGRADABLE THERMO-RESPONSIVE POLYMERS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-06-09 | — | — | WO | disclosed |
| US-9289413-B2 | Prostamide-containing intraocular implant | ALLERGAN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160038596-A1 | INJECTABLE CONTROLLED RELEASE COMPOSITION COMPRISING HIGH VISCOSITY LIQUID CARRIER | DURECT CORPORATION (US) | 2016-02-11 | — | — | US | disclosed |
| US-9233072-B2 | Adjuvant incorporation in immunonanotherapeutics | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150152440-A1 | MODIFIED MICROORGANISMS AND METHODS OF CO-PRODUCING BUTADIENE WITH 1-PROPANOL AND/OR 1,2-PROPANEDIOL | BRASKEM S.A. (BR) | 2015-06-04 | — | — | US | disclosed |
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20130129790-A1 | Adjuvant Incorporation in Immunonanotherapeutics | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2013-05-23 | — | — | US | disclosed |
| EP-2455414-A1 | Process for the production of resorbable polyesters | Evonik Röhm GmbH (DE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2455415-A1 | Method for manufacturing low-molecular resorbable polyesters, low-molecular resorbable polyester manufactured according to the method and application of same | Evonik Röhm GmbH (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20100216902-A1 | Method for the pretreatment, reprocessing or recycling of thermoplastic material | EREMA ENGINEERING RECYCLING MASCHINEN UND ANLAGEN GESELLSCHAFT M.B.H. FREINDORF UNTERFELDSTRASSE 3 (AU) | 2010-08-26 | — | — | US | disclosed |
| WO-2008089488-A2 | BIODEGRADABLE INTRAVAGINAL DEVICES FOR DELIVERY OF THERAPEUTICS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008070402-A2 | INTRAOCULAR DRUG DELIVERY SYSTEMS | ALLERGAN, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CCL2, CCL11, CCL5 | TP53 2268/4885TSHR 1767/4885 |
| US-20130129790-A1 | Adjuvant Incorporation in Immunonanotherapeutics | ICOS, CD47, CD4 | TP53 842/4885TSHR 2339/4885 |
| US-20160303242-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | PAICS, PARG, PUF60 | TP53 3321/4885TSHR 3214/4885 |
| US-20160296627-A1 | INTRACAMERAL IMPLANT FOR TREATMENT OF AN OCULAR CONDITION | STRA6, IGFBP6, PDE6D | TP53 4243/4885TSHR 1620/4885 |
| US-20160199387-A1 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT | PTGIR, PTGIS, PTGFR | TP53 4240/4885TSHR 2108/4885 |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CCL2, CCL5, CCL11 | TP53 2219/4885TSHR 3441/4885 |
| US-20160038596-A1 | INJECTABLE CONTROLLED RELEASE COMPOSITION COMPRISING HIGH VISCOSITY LIQUID CARRIER | HACD3, SAMM50, HACD2 | TP53 3013/4885TSHR 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.